Biotest Laboratories Has Completed Testing of a New Anti-Bioterrorism Sterilization Challenge Test Pack; Confirms

MINNEAPOLIS, MN and BOSTON, MA, Oct 05 (MARKET WIRE)
--
Biotest Laboratories, Inc. (www.biotestlabs.com) is employing its unique
Microbial Management (Evariology) System to ensure that dangerous
pathogens found in in-coming mail -- i.e. anthrax, smallpox, ricin, etc.
-- are neutralized. Resulting evidence will become a securitized data
base, which will help federal and local law enforcement and disease
control authorities in the fight against the serious threat of
bioterrorism.

Biotest Laboratories and President Gregg Mosley, a world-renowned expert
in sterilization of medical products, have created a system for "Managing
Microbes" based on principles of Evariology that allows trending and
tracking of problematic organisms for medical manufacturers. It is a risk
management process involving proactive bioburden monitoring devices and
production environment, allowing identification and prevention of the root
causes of contamination.

"We envision application of these same principles to bioterrorism in order
that they can be used to identify various attack organisms or toxins and
potentially predict what biological may be used by terrorists and where
such an attack could occur," explained Mr. Mosley.

Working in conjunction with BioDefense Corp. of Massachusetts and the
Bioterrorism Response Laboratory of the State of Massachusetts, Biotest
has developed a challenge pack that can test the effects of numerous
types of sterilization processes at the same time. The test pack contains
proprietary biological and chemical indicators more resistant than the
typical pathogens used for bioterrorism such as anthrax. Successful
inactivation of the challenges in the test pack, assure inactivation of
potential attack organisms.

"Anthrax attacks -- either as a hoax, or the very deadly real thing -- are
a continual headache to the security community, because this dangerous
pathogen is easily sent through the mail. MailDefender III is the ONLY
equipment that actually kills anthrax, smallpox, SARS, avian flu, and many
other dangerous substances in the customer's office," said John Meyer,
President of BioDefense Corporation.

About BioDefense Corporation

BioDefense Corporation is now bringing to market MailDefender III.
BioDefense has secured a patent for the technology containing over 30
claims, and has completed independent testing from multiple laboratories
under government supervision confirming the efficacy of the technology.
Current customers for the MailDefender include the United Nations, U.S.
Military, and other high-profile government and financial institutions.
Homeland Security Presidential Directive HSPD-7 mandates all 9,000 federal
buildings to comply with anti-bioterrorism protection, potentially
creating an estimated $70 billion market for devices like MailDefender.
Headquarters are at 12 Channel Street, Boston, MA 02210. Tel:
617-778-1800.

About Biotest Laboratories, Inc.

Biotest Laboratories, Inc. was organized by Gregg A. Mosley in 1988 as a
test laboratory for manufacturers of medical products. To meet growing
customer requests, Biotest Laboratories has developed areas of Contract
Manufacturing, Packaging/Assembly, Contract Steam Sterilization,
Cleanroom/Cleanbench Testing and Certification, Validation Services,
Microbial Management (Evariology), and Training and Consulting Services.
The company has 80 employees and is headquartered at 8990 Springbrook
Drive NW, Suite 100, Minneapolis, MN 55433. Telephone 763-785-2414 or
visit www.biotestlabs.com.

For further information contact:
Joy Mosley
Biotest Laboratories, Inc.
763-785-2414
Email Contact
or
Steven Swartz
SIZZLE PR
978-524-9595
Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-